| Literature DB >> 34786331 |
Tomohiro Fujiwara1,2, Koichi Ogura1, Alexander Christ1, Meredith Bartelstein1, Shachar Kenan1, Nicola Fabbri1, John Healey1.
Abstract
Limb-salvage surgery for pelvic sarcomas remains one of the most challenging surgical procedures for musculoskeletal oncologists. In the past several decades, various surgical techniques have been developed for periacetabular reconstruction following pelvic tumor resection. These methods include endoprosthetic reconstruction, allograft or autograft reconstruction, arthrodesis, and hip transposition. Each of these procedures has its own advantages and disadvantages, and there is no consensus or gold standard for periacetabular reconstruction. Consequently, this review provides an overview of the clinical outcomes for each of these reconstructive options following pelvic tumor resections. Overall, high complication rates are associated with the use of massive implants/grafts, and deep infection is generally the most common cause of reconstruction failure. Functional outcomes decline with the occurrence of severe complications. Further efforts to avoid complications using innovative techniques, such as antibiotic-laden devices, computer navigation, custom cutting jigs, and reduced use of implants/grafts, are crucial to improve outcomes, especially in patients at a high risk of complications.Entities:
Keywords: Acetabulum; Limb-salvage; Pelvis; Reconstruction; Sarcoma
Year: 2021 PMID: 34786331 PMCID: PMC8577502 DOI: 10.1016/j.jbo.2021.100396
Source DB: PubMed Journal: J Bone Oncol ISSN: 2212-1366 Impact factor: 4.072
Summary of the major studies for periacetabular reconstruction using an endoprosthesis following pelvic tumor resection.
| Type of prosthesis | Name/company (country) | No. of patients | Follow-up period | Functional score | Deep infection (%) | Major complication* (%) | Implant/graft survival | Author | Year | Refs |
|---|---|---|---|---|---|---|---|---|---|---|
| Saddle prosthesis | Link (Germany) | 17 | 42 | MSTS, 57% | 18% | 47%/65% | NA | Cottias | 2001 | |
| Link (Germany) | 16 | 37 | MSTS, 47% | 8% | 31%/NA | NA | Kitagawa | 2006 | ||
| Link (Germany) | 15 | 36 | MSTS, 50% | 27% | NA/40% | 2-year, 40% | Renard | 2000 | ||
| Link (Germany) | 15 | 124 (6 pts) | MSTS, 57% | 20% | 47%/NA | 54% | Donati | 2012 | ||
| Link (Germany) | 17 | 146 (6 pts) | MSTS, 47% | 53% (incl. superficial infection) | NA/82% | 42% | Jansen | 2013 | ||
| PAR hemipelvic endoprosthesis/Link (Germany) | 17 | 29.4 | MSTS, 67% | 24% | 56%/NA | 2-year, 84% | Menendez | 2009 | ||
| Modular prosthesis | Modular hemipelvic endoprosthesis/Link (Germany) and Chunli (China) | 28 | 30 | MSTS, 62% | 14% | 18%/49% | NA | Guo | 2007 | |
| Modular hemipelvic endoprosthesis/Chunli (China) | 100 | 52.9 | MSTS, 57.2% | 15% | 39%/45% | NA | Guo | 2010 | ||
| Trabecular Metal/Zimmer (USA) | 10 | 59 | Harris hip score, 75 | 0% | 20%/50% | 100% | Abdel | 2017 | ||
| Flanged acetabular cup with a constrained joint | C-THA (Japan) | 18 | 39 | Excellent 1, good 11, fair 1, poor 6 | 17% | NA/33% | 89% | Uchida | 1996 | |
| C-THA/JMM (Japan) and Kobelco (Japan) | 25 | 163 | MSTS, 55% | 32% | 52%/NA | 76% | Ueda | 2013 | ||
| C-THA/JMM (Japan) and Kobelco (Japan) | 80 | 65 | MSTS, 43% | 39% | NA/59% | 2-year, 73% | Ogura | 2018 | ||
| Custom-made endoprosthesis | Stanmore (UK) | 35 | 84 | MSTS, 70% | 26% | 40%/60% | NA | Abudu | 1997 | |
| Howmedica (Germany) | 12 | 57 | MSTS, 39% | 25% | 67%/83% | 42% | Ozaki | 2002 | ||
| Howmedica (Germany) | 9 | 62 | NA | 22% | NA/56% | 78% | Muller | 2002 | ||
| Kinergy Mechatronics (China) | 10 | 34 | Good 7, fair 2, poor 1 | 30% | 40%/NA | NA | Dai | 2007 | ||
| Stanmore (UK) | 98 | 65 | TESS, 59.4% | 30% | 32%/58% | 5-year, 76% | Jaiswal | 2008 | ||
| MUTARS/Implant cast (Germany) | 40 | 24 | MSTS, 50% | 30% | 58%/75% | 3-year, 61.4% | Witte | 2009 | ||
| Stemmed acetabular components | Ice-cream cone prosthesis/Stanmore (UK) | 27 | 39 | TESS, 69% | 11% | 19%/37% | 96% | Fisher | 2011 | |
| Pedestal cup/Zimmer (Germany) | 19 | 39 | MSTS, 49% | 47% | NA/79% | 5-year, 50% | Bus | 2014 | ||
| Pedestal cup/Zimmer (Germany) | 48 | 79 | MSTS, 71% | 17% | NA/40% | 5-year, 61% | Hipfl | 2017 | ||
| LUMiC prosthesis/Implantcast (Germany) | 47 | 47 | MSTS, 70% | 28% | NA/30% (mechanical) | 5-year, 82.7% | Bus | 2017 |
*Complications which required at least one further operation; NA, not available.
Summary of the major studies for periacetabular reconstruction using an allograft, autograft, hip transposition, and arthrodesis, following pelvic tumor resection.
| Surgical procedures | No. of patients (acetabular cases) | Follow-up period (mean, months) | Functional score | Deep infection (%) | Major complication* (%) | Implant/graft survival | Author | Year | Refs |
|---|---|---|---|---|---|---|---|---|---|
| Allograft/APC | 22 (19) | 48 | Good 1, fair 2 | 36% | 27%/72% | 73% | Ozaki | 1996 | |
| 17 | NA | MSTS, 62% | 12% | 29%/88% | 71% | Bell | 1997 | ||
| 19 | 57 | Excellent 1, good 6, fair 5, failure 6 | 26% | 42%/42% | 63% | Yoshida | 2000 | ||
| 13 (10) | 58 | MSTS, 56.4% | 15% | NA/38% | N/A | Langlais | 2001 | ||
| 35 | 120 | MSTS, 72% | 23% | NA/50% | 75% | Donati | 2011 | ||
| 33 | 33 | MSTS, 70% | 15% | NA/55% | 87.3% | Campanacci | 2012 | ||
| Pasteurized autograft | 11 | 40 | MSTS, 61% | 9% | 18%/27% | 91% | Kim | 2007 | |
| 14 | 87 | MSTS, 81.7% | 21% | 57%/NA | 5-year, 64.3% | Jeon | 2007 | ||
| 10 | 45 | MSTS, 70.5% | 10% | NA/20% | NA | Guo | 2017 | ||
| Extracorporeally irradiated autograft | 15 | 54 | EMSOS, 54% | 20% | NA/87% | NA | Sys | 2002 | |
| 18 | 52 | MSTS, 77% | 17% | NA/83% | 17% | Wafa | 2014 | ||
| Frozen autograft | 3 | 32 | Excellent 1, good 1, fair 1 | 67% | NA/67% | NA | Tsuchiya | 2005 | |
| 5 | 101 | Excellent 2, good 1, fair 2 | 20% | NA/20% | 20% | Igarashi | 2014 | ||
| Arthrodesis | 21 | 97 | MSTS, 71% | NA | NA/NA | NA | Fuchs | 2002 | |
| 5 | 50 | MSTS, 63% | 0% | 0%/40% | NA | Carmody Soni | 2012 | ||
| 4 | 136 | MSTS, 69% | 25% | 50%/50% | 75% | Nagoya | 2012 | ||
| Ipsilateral femoral autograft | 10 | 40 | MSTS, 83% | 10% | 50%/80% | 100% | Laffosse | 2012 | |
| Hip transposition | 17 | 46 | MSTS, 66% | 0% | 0% (due to infection and LR)/41% | NA | Hillmann | 2003 | |
| 20 | 69 | MSTS, 61% | 0% | 0% (due to infection and LR)/30% | 100% | Hoffmann | 2006 | ||
| 62 | 29 | MSTS, 62% | 32% | 40%/NA | NA | Gebert | 2011 | ||
| 7 | 57 | MSTS, 63% | 0% | 29%/NA | 100% | Kunisada | 2019 |
*Complications which required at least one further operation; NA, not available.
Fig. 1Radiograph of a patient who underwent periacetabular reconstruction using a saddle prosthesis.
Fig. 2Radiograph of a patient who underwent periacetabular reconstruction using a custom-made prosthesis.
Fig. 3Radiograph of a patient who underwent periacetabular reconstruction using an allograft-prosthesis composite.
Fig. 4Radiograph of a patient who underwent hip transposition arthroplasty.